Type of article: Research article

First and second waves of coronavirus disease-19: A comparative study in

hospitalized patients in Reus, Spain

Simona Iftimie [1], Ana F. López-Azcona [1], Immaculada Vallverdú [2], Salvador Hernàndez-Flix

[3], Gabriel de Febrer [4], Sandra Parra [1], Anna Hernández-Aguilera [5,6], Francesc Riu [5], Jorge

Joven [6], Jordi Camps [6,*], Antoni Castro [1], and the REUSCOVID Study Group

[1] Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d'Investigació

Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Spain

[2] Intensive Care Unit, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere

Virgili, Universitat Rovira i Virgili, Reus, Spain

[3] Section of Pneumology, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere

Virgili, Universitat Rovira i Virgili, Reus, Spain

[4] Intermediate Care Unit, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere

Virgili, Universitat Rovira i Virgili, Reus, Spain

[5] Department of Pathology, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere

Virgili, Universitat Rovira i Virgili, Reus, Spain

[6] Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària

Pere Virgili, Universitat Rovira i Virgili, Reus, Spain

Short title: Comparison between the first and the second waves of COVID-19

Collaborators of the REUSCOVID Study Group:

(In alphabetical order)

Natàlia Andreychuk, Gerard Baiges-Gaya, Frederic Ballester, Marc Benavent, José Burdeos, Alba

Català, Èric Castañé, Helena Castañé, Josep Colom, Mireia Feliu, Xavier Gabaldó, Diana Garrido,

Pedro Garrido, Joan Gil, Paloma Guelbenzu, Carolina Lozano, Francesc Marimon, Pedro Pardo,

Isabel Pujol, Antoni Rabassa, Laia Revuelta , Marta Rios, Neus Rius-Gordillo, Elisabet Rodríguez-

Tomàs, Wojciech Rojewski, Esther Roquer-Fanlo, Noèlia Sabaté, Anna Texidó, Carlos Vasco.

30
31
32

Abstract

Many countries have seen a two-wave pattern in reported cases of coronavirus disease-19 during the 2020 pandemic, with a first wave during spring followed by the current second wave in late summer and autumn. Empirical data show that the characteristics of the effects of the virus do vary between the two periods. Differences in age range and severity of the disease have been reported, although the comparative characteristics of the two waves still remain largely unknown. Those characteristics are compared in this study using data from two equal periods of 3 and a half months. The first period, between 15th March and 30th June, corresponding to the entire first wave, and the second, between 1st July and 15th October, corresponding to part of the second wave, still present at the time of writing this article. Two hundred and four patients were hospitalized during the first period, and 264 during the second period. Patients in the second wave were younger and the duration of hospitalization and case fatality rate were lower than those in the first wave. In the second wave, there were more children, and pregnant and post-partum women. The most frequent signs and symptoms in both waves were fever, dyspnea, pneumonia, and cough, and the most relevant comorbidities were cardiovascular diseases, type 2 diabetes mellitus, and chronic neurological diseases. Patients from the second wave more frequently presented renal and gastrointestinal symptoms, were more often treated with non-invasive mechanical ventilation and corticoids, and less often with invasive mechanical ventilation, conventional oxygen therapy and anticoagulants. Several differences in mortality risk factors were also observed. These results might help to understand the characteristics of the second wave and the behaviour and danger of SARS-CoV-2 in the Mediterranean area and in Western Europe. Further studies are needed to confirm our findings.

Keywords: COVID-19; Epidemiology; Mortality; Pandemic; SARS-CoV-2.

Introduction

Coronavirus disease-19 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic, giving rise to a serious health threat globally. Several countries have seen a two-wave pattern of reported cases, with a first wave in spring and a second in late summer and autumn [1-6]. In Spain, the first wave of COVID-19 began in early March 2020, although some isolated cases had been reported in February [7]. As a consequence of the first outbreak, the Spanish Government introduced a series of strict prevention measures, including home confinement, which lasted from 13th March to 4th May, followed by a three-month period of progressively increasing social interaction, work and commercial activity. As of July, life in the country had returned to relative normality, except for the mandatory wearing of a face mask and maintaining a safe social distance. Unfortunately, the number of cases of patients with COVID-19 began to increase towards the end of August and a month later it once again presented numbers similar to those in April. This forced the Government to reintroduce serious restrictive measures, including local and regional lockdowns, closures of bars, restaurants, cultural and sports activities, and a general curfew after 10 pm. The second wave of COVID-19 had been predicted months earlier and had already occurred in other countries [4]. The vast majority of Western European countries are currently suffering the consequences of this second wave and are taking similar restrictive measures. However, empirical data would suggest that this second wave differs from the first in such factors as age range and severity of the disease [8]. Indeed, it has been suggested that this second wave in Europe might be linked to the appearance of a new variant of the SARS-CoV-2, termed 20A.EU1, which appears to have originated in Spain, from where it then spread to the rest of Europe through tourists who had spent their summer holidays in that area [9]. The similarities and differences between the characteristics of the two waves remain largely unknown. Population comparison is difficult because the technological and logistical capacity of the countries in detection and diagnosis of asymptomatic patients and those with mild symptoms has

improved greatly in the six months since spring, and it is assumed that the incidence of infection in

the early months of the pandemic was much higher than had been reported [10]. However, a more

accurate comparison of the two waves is feasible through the study of the hospitalized patients for

whom disease was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) and

severe symptoms.

This study investigated the severity and characteristics of the two waves in hospitalized

patients in Reus, Spain. We evaluated age, gender, symptoms, comorbidities, mortality, supportive

care, medication, and the outcome for the patient.

Materials and Methods

Study design

We conducted a prospective study of all hospitalized cases of SARS-CoV-2 infection in

Hospital Universitari de Sant Joan, in Reus, Spain, admitted between 15th March and 15th October

2020. All patients admitted up to 30th June were considered to be in the first wave and all those

admitted from 1st July in the second wave, which divided the study period into two equal parts of

three and a half months. The only inclusion criterion was to be a hospitalized patient with an

analytical diagnosis of SARS-CoV-2. We excluded those with suspected SARS-CoV-2 infection but

had no laboratory confirmation and those who came to the hospital with symptoms compatible with

COVID-19 but did not require hospitalization. SARS-CoV-2 infection was confirmed by RT-PCR

using swab samples from the upper respiratory tract (nasopharyngeal/oropharyngeal exudate), from

the lower respiratory tract (sputum/endotracheal aspirate/bronchoalveolar lavage/bronchial aspirate)

or from the lower digestive tract (rectal smear). Tests were carried out with the VIASURE *SARS-*

CoV-2 Real Time PCR Detection Kit (CerTest Biotec, Zaragoza, Spain), or with the Procleix®

method in a Panther automated extractor and amplifier (Grifols Laboratories, Barcelona, Spain).

This study was approved by the *Comitè d'Ètica i Investigació en Medicaments* (Institutional

Review Board) of *Hospital Universitari de Sant Joan* (Resolution CEIM 040/2018, amended on 16

April 2020).

Calculation of sample size

108 Accepting an alpha risk of 0.05 and a beta risk of less than 0.2 in a bilateral contrast, it takes

109 137 subjects in the first wave and 105 in the second wave to detect a difference equal to or greater

110 than 8 years in the variable age. The common standard deviation is assumed to be 22. A follow-up

111 loss rate of 0% was estimated.

Statistical analyses

113 Data is given as numbers and percentages or means and standard deviations. Statistical

114 comparisons between two groups were made using the χ^2 test (categorical variables) or the

115 Student's *t* test. Logistic regression models were fitted to investigate the combined effect of selected

116 variables on mortality. Statistical significance was set at $p \leq 0.05$. All calculations were made using

117 the SPSS 25.0 statistical package (SPSS Inc., Chicago, IL, USA).

Results

The raw data of this study are as Supporting Information. During the study period, 468

patients with SARS-Co-V2 infection, confirmed by RT-PCR, were admitted to the hospital. The

seasonal distribution of hospital admissions is shown in Figure 1. The first wave peaked at the end

of March and was followed by a progressive decrease with very few patients being admitted in May

and June. The number of cases fluctuated upward from mid-July until a sharp increase in mid-

October. The number of patients admitted was 204 in the first wave and 264 in the second one.

Those in the second wave were significantly younger (58 ± 26 *vs*. 67 ± 18 years; p <0.001). A

noteworthy feature of the second wave was the high number of children between 0 and 9 years of

age (n = 21), 12 of them being babies under 1 year (Figure 2). The department to which the patients

were admitted is shown in Table 1. The second wave caused a significantly higher number of

admissions to Gynecology, Pediatrics and Emergency Departments and fewer to Internal Medicine

and ICU. The duration of hospitalization was significantly shorter in the second wave (14 ± 19 *vs.*

22 ± 25 days; p < 0.001). A total of 49 deaths occurred during the first wave and 35 during the

second wave, so the case fatality rate decreased from 24.0% to 13.2%. The patients who died were

significantly older than the survivors and those who died in the second wave were older than those

in the first wave (83 ± 10 *vs.* 78 ± 13 years; p = 0.042).

Figure 1.- Number of patients with COVID-19 admitted per day over the entire study period.

Figure 2.- Distribution by age intervals of the patients admitted for COVID-19 during the first

and second waves. The *p* values were calculated using the χ^2 test.

Table 1. Distribution of the hospitalized patients in the first and second waves.
140

Department	First wave (n = 204)	Second wave (n = 264)	*p*-value
Internal Medicine	124 (60.8)	123 (46.6)	0.004
Intermediate Care Unit	42 (20.6)	47 (17.8)	0.596
Intensive Care Unit	35 (17.1)	19 (7.2)	0.029
Emergency Unit	0 (0.0)	33 (12.5)	N.A.
Pediatrics	0 (0.0)	22 (8.3)	N.A.
Gynecology	0 (0.0)	10 (3.8)	N.A.
Surgery	1 (0.5)	5 (1.9)	0.102
Oncology	1 (0.5)	3 (1.1)	0.317
Traumatology	1 (0.5)	2 (0.8)	0.564

141
142   Statistical analysis was performed by the χ^2 test. Results are shown as number of cases and percentages (in parenthesis).
143   N.A.: Not applicable. The statistical test cannot be performed when one of the variables is equal to 0.
144

The relationships between COVID-19 and the clinical and epidemiological variables are

shown in Figure 3 and Table 2. The most frequent signs and symptoms in both waves were fever,

dyspnea, pneumonia, and cough (Figure 3A). The most relevant comorbidities were cardiovascular

diseases, type 2 diabetes mellitus, and chronic neurological diseases (Figure 3B). Patients from the

second wave differed from those of the first wave in that they more frequently presented a higher

frequency of vomiting, astenia, abdominal pain, rhinorrhea, or acute kidney failure, and less

frequently a cough or chills. There was no significant difference in the frequency of concomitant

chronic diseases. One result that we consider noteworthy is the considerably higher frequency in the

second wave of pregnant women who went to the hospital to give birth and post-partum women.

Figure 3.- Distribution of symptoms and diseases associated with SARS-CoV-2 infection (A)

and comorbidities and gestational variables (B) in patients admitted for COVID-19 during the

first and second waves. The p values were calculated using the χ^2 test. AKF, acute kidney failure;

ARDS, acute respiratory distress syndrome; CKD, chronic kidney disease; CLD, chronic liver

disease; CLUD, chronic lung disease; CND, chronic neurological disease; CVD, cardiovascular

disease; T2DM, type 2 diabetes mellitus.

Table 2. Clinical and epidemiological characteristics of patients with COVID-19 infection.
161

Feature	First wave (n = 204)	Second wave (n = 264)	*p*-value
Epidemiological characteristics			
Age	67 ± 18	58 ± 26	< 0.001
Gender, male	114 (55.9)	144 (54.5)	0.423
Smoking habit	10 (4.9)	27 (13.2)	< 0.001
Alcohol consumption	10 (4.9)	15 (7.3)	0.421
Signs and symptoms			
Fever	134 (65.6)	170 (64.3)	0.845
Dyspnea	122 (59.8)	134 (50.7)	0.061
Pneumonia	119 (58.3)	140 (53.8)	0.262
Cough	103 (50.5)	107 (40.5)	0.039
Diarrhea	44 (21.5)	46 (17.4)	0.288
Chills	42 (20.5)	7 (2.6)	< 0.001
Acute kidney failure	22 (10.2)	46 (17.4)	0.048
Odynophagia	14 (6.8)	15 (5.6)	0.700
Acute respiratory distress syndrome	10 (4.9)	17 (6.4)	0.552
Vomiting	9 (4.4)	39 (14.7)	< 0.001
Other symptoms[1]	12 (5.8)	69 (26.1)	< 0.001
Comorbidities and gestational variables			
Cardiovascular disease (including hypertension)	108 (52.9)	144 (54.5)	0.502
Type 2 diabetes mellitus	56 (27.4)	64 (24.2)	0.456
Chronic neurological disease	45 (22.0)	52 (19.7)	0.429
Chronic kidney disease	32 (15.6)	34 (12.9)	0.359
Chronic lung disease	31 (15.2)	47 (17.8)	0.401
Cancer	29 (14.2)	43 (16.3)	0.816
Other infectious diseases	6 (2.9)	10 (3.8)	0.464
Chronic liver disease	5 (2.4)	17 (6.4)	0.069
Postpartum (< 6 weeks)	2 (0.9)	15 (5.7)	0.024
Pregnancy	1 (0.4)	12 (4.5)	0.016

162
Statistical analysis was performed by the χ^2 test (categorical variables) or the Student's t test (quantitative variables).
Results are shown as number of cases and percentages (in parenthesis) or as means ± standard deviations.

[1] Asthenia, rhinorrhea or abdominal pain.

We also evaluated the differences in treatments between the two groups of patients. Subjects

from the second wave were treated more often with non-invasive mechanical ventilation and

corticoids, and less often with invasive mechanical ventilation, conventional oxygen therapy and

anticoagulants (Table 3). Regarding other treatments, patients in the first wave received lopinavir,

ritonavir and hydroxychloroquine, while those in the second wave received remdesivir and

tocilizumab.

Table 3. Main treatments of patients with COVID-19 infection.
173

Treatment	First wave (n = 204)	Second wave (n = 264)	*p*-value
Noninvasive mechanical ventilation	7 (3.4)	25 (9.5)	0.007
Invasive mechanical ventilation	27 (13.2)	11 (4.2)	< 0.001
High-flow oxygen therapy	18 (8.8)	28 (10.6)	0.315
Conventional oxygen therapy	155 (76.0)	156 (59.1)	< 0.001
Anticoagulants	184 (90.2)	188 (71.2)	< 0.001
Corticosteroids	86 (42.2)	156 (59.1)	< 0.001

174
Statistical analysis was performed by the χ^2 test. Results are shown as number of cases and percentages (in parenthesis).

Finally, we wanted to identify which factors were the most important determinants of death

in the two groups of patients. Logistic regression analyses highlighted the importance of age, fever,

dyspnea, acute respiratory distress syndrome, type 2 diabetes mellitus, and cancer in the first wave

(Table 4), and of age, gender, smoking habit, acute respiratory distress syndrome, and chronic

neurological diseases in the second wave (Table 5).

Table 4. Logistic regression analysis on the relationships of comorbidities with deaths for patients from the first
wave of COVID-19.

Variable	B	SE	Exp (B)	*p*-value
Age	0.096	0.024	1.101	< 0.001
Gender	0.365	0.517	1.441	0.480
Smoking habit	0.060	0.352	1.062	0.865
Alcohol consumption	-0.570	0.468	0.565	0.223
Fever	2.138	0.658	8.481	0.001
Cough	0.238	0.581	1.269	0.682
Pneumonia	-1.139	0.651	0.320	0.080

Odynophagia	-2.107	1.148	0.122	0.067
Chills	-1.288	0.760	0.276	0.090
Dyspnea	1.365	0.628	3.915	0.030
Vomiting	-1.132	1.481	0.322	0.445
Diarrhea	-0.846	0.657	0.429	0.198
Acute respiratory distress syndrome	3.606	1.185	36.828	0.002
Acute kidney failure	0.442	0.769	1.556	0.565
Other symptoms[1]	0.192	0.964	1.211	0.843
Type 2 diabetes mellitus	1.298	0.505	3.662	0.010
Cardiovascular diseases	0.114	0.559	1.121	0.839
Chronic liver diseases	0.122	1.371	1.130	0.929
Chronic lung diseases	-0.458	0.682	0.632	0.502
Chronic kidney diseases	-0.256	0.665	0.774	0.701
Chronic neurological diseases	-0.547	0.598	0.579	0.360
Other infectious diseases	0.476	1.705	1.610	0.780
Cancer	1.518	0.595	4.565	0.011
Pregnancy	-31.735	42695.071	0.000	0.999
Postpartum	20.726	40192.969	0.1×10^9	1.000
Constant	-10.394	2.044	0.000	< 0.001

186 Model summary: log-likelihood(-2) = 136.623; r^2 Cox & Snell = 0.343; r^2 Nagelkerke= 0.515; p <0.001. B: Non-
187 standardized β coefficient. SE: Standard error of B.

188 [1] Asthenia, rinorrhea or abdominal pain.

190 **Table 5. Logistic regression analysis on the relationships of comorbidities with deaths for patients from the**
191 **second wave of COVID-19.**

Variable	B	SE	Exp (B)	*p*-value
Age	0.094	0.030	1.098	0.002
Gender	1.755	0.716	5.782	0.014
Smoking habit	-2.874	1.446	0.056	0.047
Alcohol consumption	0.558	0.789	1.747	0.479
Fever	-0.583	0.756	0.558	0.441
Cough	-0.173	0.641	0.841	0.787
Pneumonia	0.186	0.744	1.204	0.803
Odynophagia	-16.683	8820.456	0.000	0.998
Chills	-18.312	12533.763	0.000	0.999
Dyspnea	-0.305	0.708	0.737	0.666
Vomiting	-1.544	1.335	0.214	0.247
Diarrhea	-1.329	1.319	0.265	0.313
Acute respiratory distress syndrome	2.242	0.988	9.410	0.023

Acute kidney failure	0.195	0.765	1.216	0.799
Other symptoms[1]	0.485	0.605	1.624	0.423
Type 2 diabetes mellitus	0.183	0.599	1.201	0.759
Cardiovascular diseases	0.276	0.832	1.318	0.740
Chronic liver diseases	2.419	1.249	11.234	0.053
Chronic lung diseases	0.178	0.697	1.195	0.799
Chronic kidney diseases	0.234	0.835	1.264	0.779
Chronic neurological diseases	1.945	0.723	6.993	0.007
Other infectious diseases	2.042	1.451	7.704	0.160
Cancer	0.289	0.626	1.335	0.644
Pregnancy	-11.766	10235.783	0.000	0.999
Postpartum	-0.555	0.542	0.574	0.306
Constant	-10.590	2.789	0.000	< 0.001

Model summary: log-likelihood(-2) = 98.286; r^2 Cox & Snell = 0.318; r^2 Nagelkerke= 0.597; p <0.001. B: Non-standardized β coefficient. SE: Standard error of B.

[1] Asthenia, rinorrhea or abdominal pain.

Discussion

We have previously reported the main epidemiological and clinical characteristics and the mortality risk factors of the first wave patients during a month and a half between March and April [11]. In the present investigation we extended the study to mid-October to cover two equal periods of three and a half months. More patients were admitted during the second wave, they were younger and there were fewer deaths, in agreement with results reported by previous research in several countries [2,3,12]. The reasons for the clear differences between the two periods are not yet known although it has been suggested that a new variant of SARS-CoV-2 emerged in early summer 2020 in Spain [9], a variant that was linked to outbreaks among young agricultural workers in the north-east of the country. Transmission to the general population in that area was then replicated across the country. Furthermore, poor compliance with social distancing guidelines by young people might have facilitated contagion in young, healthy adults and children [2,13]. The decrease in the age of the patients then resulted in a decrease in the case fatality rate in that those patients who died were

on average 5 years older than the victims of the first wave. Moreover, fewer patients required

respiratory assistance via invasive mechanical ventilation methods. This improvement in the results

of admitted patients might be linked to the fact that the health system in our country, as in many

others, has since become better prepared. We have more experience and better treatment regimens,

and we carry out more diagnostic tests, allowing serious cases to be detected early and to receive

more effective treatments. In this regard, during the second period, patients were treated more

frequently with dexamethasone, as suggested by the RECOVERY study [14], and

hydroxychloroquine and loponavir-ritonavir were substituted by remdesivir and tocilizumab, which

several studies have reported to be more effective than in preventing death and shortening the

duration of hospital stays [15-17]. Another factor that might have contributed to the decrease in the

case fatality rate is the improvement in environmental conditions. For example, warm weather and

improved air quality following the city lockdown have been reported to correlate negatively with

SARS-CoV-2 transmissibility [18-20].

A new and remarkable characteristic of the incidence of COVID-19 in this second wave in

our population is the higher incidence in babies, children and pregnant women who went to the

hospital to give birth or in post-partum women. The vast majority of these patients did not present

serious symptoms and so did not require hospitalization for more than 4 days. There were no deaths

among children up to 9 years of age, pregnant or post-partum women. The predominant symptom

presented by the children was fever (19 out of 21 cases, 90.5%), while pregnant and post-partum

women (13 and 17 cases, respectively) were asymptomatic and promptly discharged. These results

highlight the role of family contact in the transmission of the virus and agree with previous reports

that have indicated the generally low severity of the disease in these patients [21-24].

The predominant symptoms of infection (fever, dyspnea, pneumonia cough) were similar in

both waves, although the patients in the second wave presented renal (acute kidney failure) and

gastrointestinal symptoms (vomiting, abdominal pain) more frequently. Indeed, the Spanish

Ministry of Health has already highlighted, in a document updated on 2nd October, the higher

incidence of the latter in the second wave [25]. The present study did not find any differences

between the frequency of concomitant diseases in the two waves, similar findings to those of our

preliminary study [9]. In this respect, we differ from a previous study conducted in Japan that has

reported a lower incidence of cardiovascular and cerebrovascular diseases [3].

Lastly, regarding the risk factors associated with mortality, we also found differences

between the first and second waves. Multiple regression analysis showed that older age and the

presence of fever, dyspnea, acute respiratory distress syndrome, diabetes, and cancer were

independently associated with higher mortality in the first wave, while age, gender, and the

presence of acute respiratory distress syndrome and chronic neurological diseases were associated

with mortality in the second. This might be a reflection of a better management of cancer or

diabetes patients. On the other hand, the association of neurological diseases with mortality might

be due to the higher mean age of those who died in this second wave.

249 Conclusion

The results of the present study show that hospitalized patients in the second wave were

younger, required fewer days of hospitalization, had lower mortality rates and treatments were more

effective and less intensive. Although the majority of symptoms were similar in both periods, the

higher incidence of gastrointestinal symptoms in the second wave stands out as a difference.

Comorbidities were similar, but there were differences between those associated with mortality,

highlighting the importance of chronic neurological diseases in this second wave. An important

difference was the high incidence of babies, children and pregnant and post-partum women

admitted but, in general, these cases were not serious and were resolved promptly and successfully.

These results might help to understand the characteristics of this second wave and the behaviour

and danger of SARS-CoV-2 in the Mediterranean area and in Western Europe generally. Further

studies are needed to confirm our findings.

Acknowledgments

The authors are indebted to all the staff of the *Hospital Universitari de Sant Joan*, doctors, nurses, assistants, cleaning and security personnel, and all the volunteer students, who with their enormous effort are managing to overcome this dramatic situation. Editorial assistance was provided by Phil Hoddy at the Service of Linguistic Resources of the *Universitat Rovira i Virgili*.

CRediT authorship contribution statement

Simona Iftimie: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Funding acquisition, Writing-original draft, Writing-review & editing. **Ana F. López-Azcona:** Data curation, Investigation, Methodology, Writing-review & editing. **Immaculada Vallverdú:** Investigation, Resources. **Salvador Hernández-Flix:** Investigation, Resources. **Gabriel de Febrer:** Investigation, Resources. **Sandra Parra:** Investigation, Resources. **Anna Hernández-Aguilera:** Data curation, Investigation, Methodology, Writing-original draft, Writing-review & editing. **Francesc Riu:** Investigation, Resources. **Jorge Joven:** Investigation, Resources. **Jordi Camps:** Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Funding acquisition, Writing-original draft, Writing-review & editing, Supervision. **Antoni Castro:** Investigation, Resources, Funding acquisition, Writing-review & editing.

Declaration of Competing Interest

The authors declare that there are no competing interests.

Data availability

All relevant data are within the manuscript and its Supporting Information files.

References

1. Vahidy FS, Drews AL, Masud FN, Schwartz RL, Boom ML, Phillips RA, et al. Characteristics

and outcomes of COVID-19 patients during initial peak and resurgence in the Houston

metropolitan area. JAMA. 2020; 324: 998-1000. https//:doi.org/10.1001/jama.2020.15301.

2. Fan G, Yang Z, Lin Q, Zhao S, Yang L, He D. Decreased case fatality rate of COVID-19 in the

second wave: a study in 53 countries or regions. Transbound Emerg Dis. 2020;

https//:doi:10.1111/tbed.13819. Epub ahead of print.

3. Saito S, Asai Y, Matsunaga N, Hayakawa K, Terada M, Ohtsu H, et al. First and second

COVID-19 waves in Japan: A comparison of disease severity and characteristics: Comparison of

the two COVID-19 waves in Japan. J Infect. 2020: S0163-4453(20)30693-9.

https//:doi:10.1016/j.jinf.2020.10.033.

4. Renardy M, Eisenberg M, Kirschner D. Predicting the second wave of COVID-19 in

Washtenaw County, MI. J Theor Biol. 2020; 507: 110461. https://doi:

10.1016/j.jtbi.2020.110461.

5. Looi MK. Covid-19: Is a second wave hitting Europe? BMJ. 2020 ; 371: m4113. https://doi:

10.1136/bmj.m4113.

6. Win A. Rapid Rise of COVID-19 second wave in Myanmar and implications for the Western

Pacific Region. QJM. 2020; hcaa290. https://doi: 10.1093/qjmed/hcaa290.

7. Ballester-Arnal R, Gil-Llario MD. The virus that changed Spain: Impact of COVID-19 on

people with HIV. AIDS Behav. 2020; 1-5. https://doi: 10.1007/s10461-020-02877-3.

8. Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, et al. Molecular

architecture of early dissemination and massive second wave of the SARS-CoV-2 virus in a

major metropolitan area. mBio. 2020; 11: e02707-20. https://doi: 10.1128/mBio.02707-20.

9. Hodcroft EB, Zuber M, Nadeau S, Comas I, González Candelas F, et al. Emergence and spread

of a SARS-CoV-2 variant through Europe in the summer of 2020. medRxiv.

2020.10.25.20219063 [Preprint]. 2020 [cited 2020 November 18]. Available from:

https://doi.org/10.1101/2020.10.25.20219063.

10. Yang J, Chen X, Deng X, Chen Z, Gong H, Yan H, et al. Disease burden and clinical severity of

the first pandemic wave of COVID-19 in Wuhan, China. Nat Commun. 2020; 11: 5411.

https://doi: 10.1038/s41467-020-19238-2.

11. Iftimie S, López-Azcona AF, Vicente-Miralles M, Descarrega-Reina R, Hernández-Aguilera A,

Riu F, et al. Risk factors associated with mortality in hospitalized patients with SARS-CoV-2

infection. A prospective, longitudinal, unicenter study in Reus, Spain. PLoS One. 2020; 15:

e0234452. https://doi: 10.1371/journal.pone.0234452.

12. Buonanno P, Galletta S, Puca M. Spatial dynamics of SARS-CoV-2 and reduced risk of

contagion: evidence from the second Italian epidemic wave. medRxiv 2020.11.08.20227934

[Preprint]. 2020 [cited 2020 November 18]. Available from:

https://doi.org/10.1101/2020.11.08.20227934.

13. Aleta A, Moreno Y. Age differential analysis of COVID-19 second wave in Europe reveals

highest incidence among young adults. medRxiv 2020.11.11.20230177 [Preprint]. 2020 [cited

2020 November 18]. Available from: https://doi.org/10.1101/2020.11.11.20230177.

14. RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL,

Linsell L. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J

Med. 2020; July 17 https://doi: 10.1056/NEJMoa2021436. [Epub ahead of print].

15. Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: Recent reports on antiviral

therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir,

favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem. 2020; 27:

4536-4541. https://doi: 10.2174/0929867327666200416131117.

16. RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with

COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;

396: 1345-1352. https://doi: 10.1016/S0140-6736(20)32013-4.

17. Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological

treatments. Eur J Pharmacol. 2020; 886: 173451. https://doi: 10.1016/j.ejphar.2020.173451.

18. Ran J, Zhao S, Han L, Liao G, Wang K, Wang MH, et al. A re-analysis in exploring the

association between temperature and COVID-19 transmissibility: an ecological study with 154

Chinese cities. Eur Respir J. 2020; 56: 2001253. https://doi: 10.1183/13993003.01253-2020.

19. Ran J, Zhao S, Han L, Chen D, Yang Z, Yang L, et al. The ambient ozone and COVID-19

transmissibility in China: A data-driven ecological study of 154 cities. J Infect. 2020; 81: e9-e11.

https://doi: 10.1016/j.jinf.2020.07.011.

20. Ran J, Zhao S, Han L, Qiu Y, Cao P, Yang Z, et al. Effects of particulate matter exposure on the

transmissibility and case fatality rate of COVID-19: A Nationwide Ecological Study in China. J

Travel Med. 2020; 27: taaa133. https:// doi: 10.1093/jtm/taaa133.

21. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children

in China. Pediatrics. 2020; 145: e20200702. https://doi: 10.1542/peds.2020-0702.

22. Shen KL, Yang YH, Jiang RM, Wang TY, Zhao DC, Jiang Y, et al. Updated diagnosis, treatment

and prevention of COVID-19 in children: experts' consensus statement (condensed version of

the second edition). World J Pediatr. 2020;16: 232-239. https://doi: 10.1007/s12519-020-00362-

4.

23. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and

maternal-fetal transmission of SARS-CoV-2: Maternal coronavirus infections and pregnancy

outcomes. Arch Pathol Lab Med. 2020 Mar 17. https://doi: 10.5858/arpa.2020-0901-SA. Epub

ahead of print.

24. Qiao J. What are the risks of COVID-19 infection in pregnant women? Lancet. 2020; 395: 760-

762. https://doi: 10.1016/S0140-6736(20)30365-2.

25. Spanish Ministry of Health. Questions and answers about the new coronavirus (COVID-19).

Updated October 2, 2020. 2020; 1-4. Available from:

https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/2

020_10_05_Preguntas_respuestas_2019-nCoV-2.pdf.